4,901 trials
Hepatic Impairment · Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) of PF-07081532 — 2236; 2121; 2230; 1536 nanogram per milliliter (ng/mL)
Trachoma
Primary: Solicited Local Injection Site Reactions — 2; 8; 3; 9 Participants — p=1
Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic
Primary: Determination of the Maximum Tolerated Dose (MTD) of Continuous Oral LAM-002A — 125 mg BID
Healthy Volunteer · Opioid-use Disorder
Primary: Part I and Part II: Number of Participants With Adverse Events — 5; 2; 3; 8 Participants
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 5441.83; 175.10 nanomole…
Healthy
Primary: Change From Baseline in Capsaicin-Induced Dermal Blood Flow Following LY3316531 Compared to Placebo — 327.19; 63.65 milliliter/100gram/minute (mL/100g/min) — p=<0.001
Healthy
Primary: Part 1: AUC0-tz of BI 409306 — 603; 643 nanomol (nmol)*hour (h)/Litre (L)
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 and Stable Labelled Isotope BI 409306 (C-13/N-15) Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)…
Healthy Adults
Primary: (Part A) Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) of Atorvastatin in Periods 1, 4, and 7 — 32.27; 46.94; 54.43 nanogram*hour/milliliter…
Healthy
Primary: Change From Baseline in Mean Daily Copper Balance Over 2 Weeks of Repeated Daily ALXN1840 Dosing (Over Days 4 to 15) — -0.0749; 0.6901; 0.4201 mg/day
Leukemia, Lymphocytic · Lymphoblastic Lymphoma · T-cell Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) of Total Dabigatran When Dabigatran Etexilate is Administered Alone Versus When Dabigatran Etexilate is Administered With…
Head and Neck Cancer
Primary: Incidence of Treatment Related Adverse Events — 4; 2; 4; 1 Participants
Rheumatoid Arthritis
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC(0-inf)) for Caffeine, Omeprazole and Midazolam — 38.23; 26.94; 1408; 955.8 h*ng/mL
Parkinson's Disease
Primary: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted…